These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 3041546)
1. Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies. Shaw P; Buckman R; Law J; Baumal R; Marks A Tumour Biol; 1988; 9(2-3):101-9. PubMed ID: 3041546 [TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. Ghosh AK; Spriggs AI; Taylor-Papadimitriou J; Mason DY J Clin Pathol; 1983 Oct; 36(10):1154-64. PubMed ID: 6194183 [TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical staining with monoclonal antibodies in cytologically "negative" serous effusions from patients with malignant disease. Ghosh AK; Mason DY; Spriggs AI J Clin Pathol; 1983 Oct; 36(10):1150-3. PubMed ID: 6194182 [TBL] [Abstract][Full Text] [Related]
4. Ca2 and Ca3. New monoclonal antibodies evaluated as tumor markers in serous effusions. Bramwell ME; Ghosh AK; Smith WD; Wiseman G; Spriggs AI; Harris H Cancer; 1985 Jul; 56(1):105-10. PubMed ID: 2408723 [TBL] [Abstract][Full Text] [Related]
5. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. Szpak CA; Johnston WW; Lottich SC; Kufe D; Thor A; Schlom J Acta Cytol; 1984; 28(4):356-67. PubMed ID: 6205527 [TBL] [Abstract][Full Text] [Related]
6. Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. Mottolese M; Venturo I; Donnorso RP; Curcio CG; Rinaldi M; Natali PG Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1277-84. PubMed ID: 3053205 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the cytodiagnosis of serous effusions. al-Nafussi A; Carder PJ Cytopathology; 1990; 1(2):119-28. PubMed ID: 1714782 [TBL] [Abstract][Full Text] [Related]
8. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146 [TBL] [Abstract][Full Text] [Related]
9. Immunoperoxidase demonstration of carcinoembryonic antigen in pleural and peritoneal effusions. Sehested M; Ralfkjaer E; Rasmussen J Acta Cytol; 1983; 27(2):124-7. PubMed ID: 6340401 [TBL] [Abstract][Full Text] [Related]
10. Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions. Epenetos AA; Canti G; Taylor-Papadimitriou J; Curling M; Bodmer WF Lancet; 1982 Nov; 2(8306):1004-6. PubMed ID: 6127499 [TBL] [Abstract][Full Text] [Related]
11. Applications of immunocytochemistry to clinical cytology. Johnston WW; Szpak CA; Thor A; Simpson JF; Schlom J Cancer Invest; 1987; 5(6):593-611. PubMed ID: 3327572 [TBL] [Abstract][Full Text] [Related]
12. Immunocytochemical reaction of Ca1 and HMFG2 monoclonal antibodies with cells from serous effusions. Singer S; Boddington MM; Hudson EA J Clin Pathol; 1985 Feb; 38(2):180-4. PubMed ID: 3881482 [TBL] [Abstract][Full Text] [Related]
13. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture. Johnston WW Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301 [TBL] [Abstract][Full Text] [Related]
14. A new marker for human cancer cells. 3. Immunocytochemical detection of malignant cells in serous fluids with the Ca1 antibody. Woods JC; Spriggs AI; Harris H; McGee JO Lancet; 1982 Sep; 2(8297):512-4. PubMed ID: 6125677 [TBL] [Abstract][Full Text] [Related]
15. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. Delahaye M; Hoogsteden HC; Van der Kwast TH J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800 [TBL] [Abstract][Full Text] [Related]
16. Immunocytochemical detection of ovarian carcinoma cells in serous effusions. Cuijpers VM; Boerman OC; Salet van de Pol MR; Vooijs GP; Poels LG; Ramaekers FC Acta Cytol; 1993; 37(3):272-9. PubMed ID: 8498129 [TBL] [Abstract][Full Text] [Related]
17. [Contribution of immunocytochemical marking of benign cells to the diagnosis of serous effusions]. Gaulier A; Cava E; Chosia MC; Pore G; Marsan C Ann Pathol; 1986; 6(4-5):323-8. PubMed ID: 3814272 [TBL] [Abstract][Full Text] [Related]
18. Utility of HBME-1 immunostaining in serous effusions. Ascoli V; Carnovale-Scalzo C; Taccogna S; Nardi F Cytopathology; 1997 Oct; 8(5):328-35. PubMed ID: 9313985 [TBL] [Abstract][Full Text] [Related]
19. Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. Martin SE; Moshiri S; Thor A; Vilasi V; Chu EW; Schlom J Am J Clin Pathol; 1986 Jul; 86(1):10-8. PubMed ID: 3524191 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions. Lee JS; Nam JH; Lee MC; Park CS; Juhng SW Acta Cytol; 1996; 40(4):631-6. PubMed ID: 8693877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]